Publications by authors named "Silvia Di Tollo"
Article Synopsis
- * A phase III trial intends to use an adaptive dosing method, where the dosage of Givinostat is adjusted every 28 days based on patient blood results, informed by a developed simulation platform.
- * Initial simulations suggest that smaller, more frequent adjustments in Givinostat dosage improve patients' chances of achieving a complete hematological response while reducing the occurrence of serious side effects compared to larger adjustments.
Article Synopsis
- Polycythemia vera (PV) is a type of blood cancer where the bone marrow produces too many blood cells, mostly due to a mutation in the JAK2 gene.
- Givinostat, a drug that inhibits cell growth related to JAK2, has shown positive results in earlier studies, prompting a long-term study on its effects in patients with PV.
- Over a 4-year follow-up of patients, givinostat was found to have a good safety profile, with only 10% experiencing serious side effects, while more than 80% showed positive treatment responses.
Article Synopsis
- Givinostat, an HDAC inhibitor, has shown effectiveness in treating patients with the JAK2 V617F mutation and chronic myeloproliferative neoplasms.
- In a phase II study, 44 polycythaemia vera patients unresponsive to hydroxycarbamide were treated with Givinostat and the response rate after 12 weeks was 55% for the 50 mg group and 50% for the 100 mg group.
- The treatment was well tolerated, with only 18% of patients discontinuing due to side effects, suggesting that Givinostat combined with hydroxycarbamide is a safe and effective option for these patients.
Article Synopsis
- A phase II study assessed the safety and effectiveness of Givinostat, a histone-deacetylase inhibitor, in patients with Polycythaemia Vera, Essential Thrombocythaemia, and Myelofibrosis who have the JAK2V617F mutation.
- The treatment involved administering Givinostat orally for 24 weeks, with some patients requiring dose adjustments or discontinuation due to side effects or disease progression.
- Results showed promising responses, especially among Polycythaemia Vera and Essential Thrombocythaemia patients, with improvements in symptoms like pruritus and splenomegaly, indicating Givinostat's potential as a tolerated treatment option.